To News

Cambrios Technologies Announces $12 Million Series B Round

Feb. 2005

Cambrios Technologies Corporation, the pioneer in applying strategies of biological systems to the assembly and synthesis of materials for solid-state electronics, announced today the first closing of $9 million toward a guaranteed $12 million Series B funding round.

In-Q-Tel, Harris & Harris Group Inc., (Nasdaq: TINY) and Headland Ventures join Series A investors Alloy Ventures, ARCH Venture Partners, Avalon Ventures, Lux Capital, and Oxford Bioscience Partners, all of whom are participating in the Series B. Cambrios will use the new funds to accelerate its development of biochemical materials for electronic manufacturing processes and other commercial products.

“Cambrios has a large vision for using biological technology in assembling inorganic materials that make up solid-state electronic devices,” said Michael Knapp, Ph.D., president and CEO of Cambrios. “Our investors have given us a great vote of confidence. We now have the resources to pursue this vision vigorously and accomplish two things: rapidly develop tangible manifestations of the technology and find commercialization partners with which to bring them to market.”

“We’re pleased to be investors in Cambrios,” said Daniel Leff, Executive Vice President & Managing Director at Harris & Harris Group. “Cambrios’ approach of liquid-phase, biologically directed, inorganic materials synthesis has the potential to be a more cost-effective fabrication alternative for a multitude of electronics applications, such as the deposition of thin films in liquid crystal display manufacturing.”

“It’s still early but if Cambrios continues hitting key milestones, it could effect one of the most profound shifts in the history of electronics manufacturing,” said Josh Wolfe, Co-Founder and Managing Partner with Lux Capital.

About Harris & Harris Group, Inc.
The Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company’s last 19 initial private equity investments have been in tiny-technology enabled companies. The Company has 17,248,845 common shares outstanding.

About Headland Ventures
Headland Ventures is a venture partnership singularly focused on building successful companies from the ground up. Headland concentrates on the connectivity provided by the next generation communications network and the companies defining its direction.

About Cambrios Technologies Corporation
Cambrios was founded in 2002 as Semzyme, Inc. based on the work of Angela Belcher Ph.D., a professor at MIT and previously at University of Texas. The company’s headquarters and laboratories are located in Mountain View, Calif. Cambrios’ technology and I.P. portfolio address the discovery of proteins that bind important inorganic materials, the use of those biomolecules to assemble nanostructures made of these materials, and the applications of these methods in processes for the construction of solid-state electronic devices. Investors in Cambrios include Alloy Ventures, ARCH Venture Partners, Avalon Ventures, Harris & Harris, Headland Ventures, In-Q-Tel, Lux Capital, and Oxford Biosciences P